title: The aminoglycosides. Streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, sisomicin.
abstract: Despite their toxicity, the aminoglycosides remain useful and are often the first choice in the treatment of serious infections due to gram-negative bacilli. Nephrotoxicity has restricted the indications for neomycin to topical and oral use. Emergence of resistant organisms has limited the use of streptomycin to a few specific conditions. Gentamicin, tobramycin, and amikacin are effective against a broad spectrum of gram-negative bacilli including Pseudomonas aeruginosa. Amikacin is the aminoglycoside of choice when gentamicin resistance is prevalent.
mesh_terms: D000583:Amikacin / Q000009:adverse effects / Q000627:therapeutic use; D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D005839:Gentamicins / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000009:adverse effects / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009428:Netilmicin / Q000009:adverse effects / Q000627:therapeutic use; D012853:Sisomicin / Q000009:adverse effects / Q000627:therapeutic use; D013307:Streptomycin / Q000009:adverse effects / Q000627:therapeutic use; D014031:Tobramycin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; D009428:Netilmicin; D007612:Kanamycin; D000583:Amikacin; D014031:Tobramycin; D012853:Sisomicin; D013307:Streptomycin